Bacterial-based Cancer Vaccine Development Services
As researchers gain insights into the immune reactions against invading tumors and their underlying mechanisms, immunotherapy is emerging as a strategy to combat tumor growth. Harnessing bacteria and bacterial components to combat cancer shows promise and holds the potential to address the evolving challenges in cancer management. Alfa Cytology is dedicated to delivering top-notch research and development services in this domain, providing superior bacterial-based cancer vaccines to drive scientific progress forward.
Bacterial Immunotherapy in Cancer
Bacteria function as innate immune antigens, prompting the immune system to eliminate tumors by activating immune cells. As early as the 19th century, injections of streptococcus pyogenes were employed to treat patients with sarcoma, highlighting their therapeutic potential in cancer management. At present, many investigations have scrutinized the complex immune reactions initiated by bacteria within the tumor microenvironment. Across diverse cancer models, bacterial infiltration into tumors, immune response stimulation, and tumor lysis induction have been observed. Furthermore, bacteria and their derivatives contain various pathogen-associated molecular patterns capable of triggering immune responses.
Fig. 1 Regulation of immune cells by bacteria, bacterial components, and their derivatives. (Zhou, M., et al., 2023)
Our Service
The efficacy of bacterial vaccines in cancer therapy stems from bacteria's genetic manipulation abilities, flagella capable of tissue penetration, and their tendency to accumulate selectively within tumors. Leveraging these advantages, Alfa Cytology offers professional and high-quality support services for bacteria-based cancer vaccine development to advance your research.
Vaccine Options and Tumor Types
We offer several types of bacteria-derived cancer vaccines, including but not limited to the following.
Investigations into bacteria-derived cancer vaccines are in nascent stages, with research pathways varying across different cancer types. Below are some prominent research directions.
Examples of such instances include vaccines that utilize genetically engineered Salmonella bacteria as carriers for delivering antigens into the body. Alfa Cytology provides bacterial vaccines tailored for pancreatic cancer.
Certain investigations have endeavored to utilize engineered Listeria monocytogenes to carry antigens associated with HPV. Alfa Cytology offers customized bacterial vaccines for cervical cancer.
Continuous research efforts are underway to investigate cancer vaccine development focusing on bacteria like Streptococcus and Helicobacter pylori. Alfa Cytology delivers individualized bacterial vaccines for gastric carcinoma.
Bacterial-based Cancer Vaccine Development Process
Antigen Selection & Design
Vaccine Preparation & Production
Selection of Suitable Carrier Bacteria
For specific tumor types or research requirements, a bacterium with optimal biosafety and immunological efficacy is carefully chosen as a vaccine vector.
Vector Bacterial Genetic Modification
The chosen cancer cell antigen gene sequences are integrated into the genome of selected vector bacteria using genetic engineering methods. This process ensures stable expression of the antigen within the bacteria without compromising their growth or immune activity.
Conducting preclinical trials to assess vaccine safety, vaccine dosage, and vaccine efficacy.
Why Choose Us?
Professional and well-trained technical team.
Advanced experimental equipment.
Empowering success through cooperation.
Strict quality control system.
Bacteria, serving as carriers of immunogens, may confer supplementary immune-stimulating effects. Given the cost-effectiveness of manufacturing and producing bacteria-based cancer vaccines, their application shows promising prospects. Based on these advantages, Alfa Cytology can support you with specialized bacteria-based cancer vaccine development services. If you wish to explore bacteria-derived cancer vaccines or require further details about our services, contact us.
Reference
- Zhou, M., et al.; (2023). Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Frontiers in immunology, 14, 1140463. https://doi.org/10.3389/fimmu.2023.1140463